GoodRx (NASDAQ:GDRX) Given New $3.00 Price Target at Mizuho

GoodRx (NASDAQ:GDRX) had its price objective reduced by Mizuho from $4.00 to $3.00 in a research report sent to investors on Friday,Benzinga reports. Mizuho currently has a neutral rating on the stock.

GDRX has been the topic of a number of other reports. Bank of America restated a “reduce” rating on shares of GoodRx in a report on Monday, January 5th. Jefferies Financial Group lowered shares of GoodRx to a “hold” rating in a research note on Thursday, January 22nd. Wall Street Zen cut shares of GoodRx from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. UBS Group dropped their price objective on shares of GoodRx from $4.25 to $4.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th. Finally, Leerink Partners restated an “outperform” rating and issued a $3.00 target price on shares of GoodRx in a research note on Thursday. Five investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $4.52.

GoodRx Trading Down 6.0%

GDRX traded down $0.12 during trading on Friday, reaching $1.87. 6,060,372 shares of the stock traded hands, compared to its average volume of 3,824,981. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81. The stock’s 50-day moving average is $2.51 and its 200 day moving average is $3.26. GoodRx has a 12 month low of $1.79 and a 12 month high of $5.81. The stock has a market capitalization of $634.74 million, a PE ratio of 20.78, a P/E/G ratio of 0.76 and a beta of 1.50.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.09 earnings per share for the quarter, hitting the consensus estimate of $0.09. GoodRx had a return on equity of 9.25% and a net margin of 3.82%.The firm had revenue of $194.79 million during the quarter, compared to analyst estimates of $193.27 million. During the same period last year, the company posted $0.09 EPS. The business’s quarterly revenue was down 1.9% on a year-over-year basis. Equities analysts anticipate that GoodRx will post 0.13 earnings per share for the current year.

Institutional Trading of GoodRx

Several institutional investors have recently made changes to their positions in the company. Quarry LP bought a new position in shares of GoodRx during the third quarter valued at about $33,000. Cetera Investment Advisers purchased a new stake in GoodRx in the 2nd quarter valued at about $50,000. Boothbay Fund Management LLC purchased a new stake in GoodRx in the 3rd quarter valued at about $43,000. Meridian Wealth Management LLC bought a new position in shares of GoodRx during the 4th quarter worth approximately $29,000. Finally, Shay Capital LLC purchased a new position in shares of GoodRx in the 3rd quarter worth approximately $47,000. Institutional investors own 63.77% of the company’s stock.

Trending Headlines about GoodRx

Here are the key news stories impacting GoodRx this week:

• Positive Sentiment: Management guided PharmaDirect revenue to grow at least 30% in 2026, signaling clearer traction in its shift toward pharma manufacturer solutions. GoodRx expects PharmaDirect revenue growth of at least 30% in 2026
• Positive Sentiment: Q4 results: EPS matched Street estimates ($0.09) and revenue modestly beat consensus (~$194.8M vs $193.3M); company highlighted a PharmaDirect surge that helped results. GoodRx Holdings Inc (GDRX) Q4 2025 Earnings Call Highlights
• Positive Sentiment: Management is prioritizing growth in digital subscriptions and self-service prescription flows, a strategy that could boost long-term unit economics if adoption improves. GoodRx Targets Digital Subscription Growth Amid 14% Dip in Active Consumers
• Neutral Sentiment: Earnings call transcript and full Q4 commentary are available for deeper read — useful for parsing management’s cadence on retention, margins and PharmaDirect progress. GoodRx Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analysts and data outlets are parsing key metrics (ARPU, active consumers, PharmaDirect mix) to reconcile the headline numbers with underlying trends. Here’s What Key Metrics Tell Us About GoodRx (GDRX) Q4 Earnings
• Neutral Sentiment: JPMorgan reaffirmed a “neutral” rating on GDRX, leaving its stance unchanged for now. JPMorgan Reaffirms Neutral Rating
• Negative Sentiment: Active consumers fell ~14% in the quarter, a meaningful top-line headwind that raises concern about user engagement and the pace of monetization. Active Consumers Down 14%
• Negative Sentiment: Mizuho lowered its price target from $4.00 to $3.00 and kept a “neutral” rating, signaling reduced near-term expectations from at least one sell-side firm. Mizuho Lowers Price Target

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.